Can personalized treatment prediction improve the outcomes, compared with the group average approach, in a randomized trial? Developing and validating a multivariable prediction model in a pragmatic megatrial of acute treatment for major depression.

[1]  Andrea Cipriani,et al.  Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol , 2019, Evidence-Based Mental Health.

[2]  Ewout W Steyerberg,et al.  Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. , 2019, Journal of clinical epidemiology.

[3]  Alan M. Zaslavsky,et al.  Machine learning methods for developing precision treatment rules with observational data. , 2019, Behaviour research and therapy.

[4]  Ewout W Steyerberg,et al.  Assessment of heterogeneity in an individual participant data meta‐analysis of prediction models: An overview and illustration , 2019, Statistics in medicine.

[5]  S. Yamawaki,et al.  Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. , 2019, Journal of affective disorders.

[6]  Ewout Steyerberg,et al.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.

[7]  Richard D Riley,et al.  A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes , 2018, Statistical methods in medical research.

[8]  G. Guyatt,et al.  Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial , 2018, BMC Medicine.

[9]  P. Cuijpers,et al.  Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression , 2018, Psychotherapy and Psychosomatics.

[10]  C. Nemeroff,et al.  The revolution of personalized psychiatry: will technology make it happen sooner? , 2017, Psychological Medicine.

[11]  Vincent Audigier,et al.  Multiple Imputation for Multilevel Data with Continuous and Binary Variables , 2017, 1702.00971.

[12]  L. Hooft,et al.  A guide to systematic review and meta-analysis of prediction model performance , 2017, British Medical Journal.

[13]  R. McIntyre,et al.  Personalized medicine in psychiatry , 2017, Nordic journal of psychiatry.

[14]  Richard D Riley,et al.  External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges , 2016, BMJ.

[15]  H. Christensen,et al.  Are personalised treatments of adult depression finally within reach? , 2016, Epidemiology and Psychiatric Sciences.

[16]  Frank E. Harrell,et al.  Prediction models need appropriate internal, internal-external, and external validation. , 2016, Journal of clinical epidemiology.

[17]  Johannes B. Reitsma,et al.  Individual Participant Data (IPD) Meta-analyses of Diagnostic and Prognostic Modeling Studies: Guidance on Their Use , 2015, PLoS medicine.

[18]  Karel G M Moons,et al.  A new framework to enhance the interpretation of external validation studies of clinical prediction models. , 2015, Journal of clinical epidemiology.

[19]  G. Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.

[20]  Karel G M Moons,et al.  A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta‐analysis , 2013, Statistics in medicine.

[21]  T. Furukawa,et al.  The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase , 2012, Trials.

[22]  T. Furukawa,et al.  Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol , 2011, Trials.

[23]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[24]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[25]  M. Fava,et al.  Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. , 2008, The Journal of clinical psychiatry.

[26]  Maurizio Fava,et al.  Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. , 2008, Archives of general psychiatry.

[27]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[28]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[29]  Patrick Royston,et al.  Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer , 2004, Statistics in medicine.

[30]  B. Rothbaum,et al.  Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma , 2003, Proceedings of the National Academy of Sciences of the United States of America.